English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Gastric cancer is still a major health problem worldwide due to its frequency, poor prognosis and limited treatment options. To study the inhibitory effect of nuclear transcription factor kappa B(NF-&#x3ba;B) antisense oligodeoxynucleotide(ASODN) on the growth and tumorgenesis of human gastric cancer, we synthesis and transfect ASODN of NF-&#x3ba;B/P65 to gastric cancer cell line. The effect of ASODN of NF-&#x3ba;B/P65 on the proliferation of gastric cancer cells was measured by MTT method. The subcutaneous xenograft model of human gastric cancer was established in nude mice and the tumor growth curve was observed. The cell proliferation was significantly inhibited in P65 ASODN transfected group in vitro (P&#x3c;0.05). In vivo, tumor formation test showed that the tumor volume in nude mice in ASODN group was obviously smaller than in other groups (P&#x3c;0.05), the apoptosis index (AI) was significantly higher (P&#x3c;0.001). Stimultaneously, MVD in ASODN group was markedly lower than in other groups (P&#x3c;0.01). Our findings suggest that P65 ASODN can inhibit gastric cancer cells proliferation and tumorgenesis by inducing cell apoptosis and inhibiting tumor angiogenesis. NF-&#x3ba;B can be used as a new biological therapeutic target of gastric cancer

Effect of antisense oligodeoxynudeotide targeted against NF-κB/P65 on cell proliferation and tumorgenesis of gastric cancer